SHERLOCK BIOSCIENCES, INC.
BRIGHTON, MA · Founded 2018 · CIK 0001774717 · Medtech · Acquired
Point-of-care STI diagnostic device for detecting Chlamydia and Gonorrhea from self-collected swabs using proprietary amplification chemistry and microfluidic control, requiring no heating, electricit
orasure.com →- Grants
- $474K
- 2 awards
- Sector median: 1
- Raised
- $113M
- 2 Form D · Mar 2022
- 54 months since last filing
- Contracts
- $3.1M
- 1 award · Health and Human S
- #167 of 4531 in medtech
- Patents
- 25
- 0 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $32,759,240 | |
| Private capital raised | Form D · SEC | $80,000,013 | |
| Federal grant | Department of Agriculture · Rapid And Accurate Health Assessment Of Farmed Animals Is Critical To US Aquaculture And Agriculture. It Is Hindered By The Cost, Time, And Technical Expertise Required For Standard Diagnostic Methods, Resulting In Reduced Capacity For Disease Control And Production Losses. Our Goal Is To Transform US Animal Production By Developing Rapid, Inexpensive, Sensitive, Field-deployable Crispr-based Diagnostics That Enable Farmers To Effectively Monitor And Respond To Disease Outbreaks, Validate Pathog | $174,957 | |
| Federal grant | Department of Health and Human Services · Phase I · Ambient Temperature Molecular Detection of Sexually Transmitted Infections from Vaginal Swabs on a Power-free Device | $298,948 | |
| Federal contract | Department of Health and Human Services · Development Of A Low-cost, Point-of-need Molecular Test For Flu A+b And Self-collected Swab Specimens. | $3,079,315 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 164 | PHOENIX BIOSYSTEM, INC. | $3.2M | — |
| 165 | MIRAVISTA DIAGNOSTICS LLC | $3.1M | — |
| 166 | SENSIMETRICS CORP | $3.1M | — |
| 167 | SHERLOCK BIOSCIENCES, INC. | $3.1M | $113M |
| 168 | SYNDAVER LABS INC. | $3.0M | $1.0M |
| 169 | ADVANCED CELL DIAGNOSTICS, INC. | $3.0M | — |
| 170 | Cardiovascular Systems | $3.0M | $5.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James CollinsDirector
- Bryan DechairoDirector · Executive Officer
- Rahul DhandaDirector · Executive Officer
- Issi RozenDirector
- Michael RubinDirector
- David WaltDirector
Patents
- Ambient Temperature Nucleic Acid Amplification And Detectionapplication
- Detection Assaysapplication
- Improved Crispr-cas Technologiesapplication
- Nucleic Acid Amplification Using Promoter Primersapplication
- Hybridisation-based Sensor Systems And Probesapplication
- Crispr-based SARS-COV-2 Detectionapplication
- Detection Assaysapplication
- Improved Detection Assaysapplication
- Ambient Temperature Nucleic Acid Amplification And Detectionapplication
- Nucleic Acid Preparationapplication
- Condensed Loop-mediated Isothermal Amplificationapplication
- Cartridge Identification Methodapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.